Filing Flows › 20/20 Biolabs (AIDX) › Stock forecast & fair value
20/20 Biolabs (AIDX) stock forecast and price target
20/20 Biolabs (AIDX) trades at $0.20. One analyst's price target is $5.00 (25×).
20/20 Biolabs' latest quarter
20/20 Biolabs, Q2 2026: revenue $731K (+36% year over year), operating margin -170.3%, net loss $1.5M, operating cash flow −$605K. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for AIDX stock?
One analyst's 12-month target is $5.00, 25× from $0.20. The average rating is none.
Does 20/20 Biolabs usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is AIDX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.